Bvf Partners L P/il - Net Worth and Insider Trading
Bvf Partners L P/il Net Worth
The estimated net worth of Bvf Partners L P/il is at least $1.4 Billion dollars as of 2024-06-21. Bvf Partners L P/il is the 10% Owner of Array BioPharma Inc and owns about 12,965,657 shares of Array BioPharma Inc (ARRY) stock worth over $505 Million. Bvf Partners L P/il is the 10% Owner of Neurocrine Biosciences Inc and owns about 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $473 Million. Bvf Partners L P/il is also the 10% Owner of Arqule Inc and owns about 16,832,292 shares of Arqule Inc (ARQL) stock worth over $337 Million. Besides these, Bvf Partners L P/il also holds ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , Arena Pharmaceuticals Inc (ARNA) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) . Details can be seen in Bvf Partners L P/il's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bvf Partners L P/il has not made any transactions after 2015-06-10 and currently still holds the listed stock(s).
Transaction Summary of Bvf Partners L P/il
Bvf Partners L P/il Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Bvf Partners L P/il owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Corp (XOMA) among others .
Click here to see the complete history of Bvf Partners L P/il’s form 4 insider trades.
Insider Ownership Summary of Bvf Partners L P/il
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
FPRX | Five Prime Therapeutics Inc | 2020-10-06 | 10 percent owner |
ELDN | Eledon Pharmaceuticals Inc | 2020-10-01 | 10 percent owner |
XOMA | XOMA Corp | 2017-02-10 | 10 percent owner |
2020-01-01 | 10 percent owner | ||
2021-06-16 | director & other: See Remarks | ||
2020-08-18 | 10 percent owner | ||
2020-06-18 | 10 percent owner | ||
2019-06-19 | 10 percent owner | ||
2017-06-09 | 10 percent owner | ||
2019-12-09 | 10 percent owner | ||
2018-11-16 | 10 percent owner | ||
2017-05-01 | 10 percent owner | ||
2017-09-19 | 10 percent owner | ||
2016-11-30 | 10 percent owner | ||
2018-12-04 | 10 percent owner | ||
2017-11-28 | 10 percent owner | ||
2018-05-30 | 10 percent owner | ||
2016-09-08 | 10 percent owner | ||
2017-11-17 | 10 percent owner | ||
2011-09-06 | 10 percent owner & other: Indirect Beneficial Owner | ||
2017-05-08 | 10 percent owner | ||
2016-06-23 | 10 percent owner | ||
2015-06-10 | 10 percent owner | ||
2012-11-16 | 10 percent owner | ||
2014-03-25 | 10 percent owner & other: Indirect Beneficial Owners | ||
2014-03-21 | other: See Explanation of Responses | ||
2011-10-05 | 10 percent owner | ||
2013-11-19 | 10 percent owner | ||
2011-10-12 | 10 percent owner & other: Indirect Beneficial Owner | ||
2009-12-22 | 10 percent owner | ||
2009-12-18 | 10 percent owner | ||
2009-10-21 | 10 percent owner | ||
2009-09-10 | 10 percent owner & other: Indirect Beneficial Owners | ||
2009-05-15 | 10 percent owner & other: Group Member | ||
2009-02-03 | 10 percent owner & other: Indirect Beneficial Owners | ||
2006-06-06 | 10 percent owner & other: Indirect Beneficial Owner | ||
2006-01-12 | 10 percent owner & other: Indirect Beneficial Owner | ||
2004-07-08 | 10 percent owner & other: Indirect Beneficial Owner | ||
2003-10-27 | 10 percent owner & other: Indirect Beneficial Owner | ||
2017-02-10 | 10 percent owner | ||
2020-12-18 | 10 percent owner | ||
2022-01-25 | 10 percent owner | ||
2021-04-22 | director & other: See Remarks | ||
2020-11-18 | director & 10 percent owner & other: See Remarks | ||
2021-12-31 | 10 percent owner | ||
2021-10-28 | 10 percent owner | ||
2022-04-05 | director & 10 percent owner | ||
2022-06-16 | 10 percent owner | ||
2022-07-11 | 10 percent owner | ||
2022-12-19 | 10 percent owner | ||
2023-02-03 | 10 percent owner | ||
2023-11-02 | 10 percent owner |
Bvf Partners L P/il Latest Holdings Summary
Bvf Partners L P/il currently owns a total of 14 stocks. Among these stocks, Bvf Partners L P/il owns 12,965,657 shares of Array BioPharma Inc (ARRY) as of June 25, 2014, with a value of $505 Million and a weighting of 35.07%. Bvf Partners L P/il owns 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) as of October 12, 2011, with a value of $473 Million and a weighting of 32.84%. Bvf Partners L P/il also owns 16,832,292 shares of Arqule Inc (ARQL) as of April 5, 2010, with a value of $337 Million and a weighting of 23.38%. The other 11 stocks ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , Arena Pharmaceuticals Inc (ARNA) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) have a combined weighting of 8.71% among all his current holdings.
Latest Holdings of Bvf Partners L P/il
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ARRY | Array BioPharma Inc | 2014-06-25 | 12,965,657 | 38.95 | 505,012,340 |
NBIX | Neurocrine Biosciences Inc | 2011-10-12 | 3,527,700 | 134.07 | 472,958,739 |
ARQL | Arqule Inc | 2010-04-05 | 16,832,292 | 20.00 | 336,645,840 |
CCXI | ChemoCentryx Inc | 2015-06-10 | 1,251,914 | 51.99 | 65,087,009 |
LGND | Ligand Pharmaceuticals Inc | 2014-03-25 | 360,300 | 79.88 | 28,780,764 |
ARNA | Arena Pharmaceuticals Inc | 2004-07-08 | 99,485 | 99.99 | 9,947,505 |
BCRX | BioCryst Pharmaceuticals Inc | 2003-10-27 | 1,455,900 | 6.14 | 8,939,226 |
RIGL | Rigel Pharmaceuticals Inc | 2013-11-19 | 6,962,123 | 0.97 | 6,724,018 |
DVAX | Dynavax Technologies Corp | 2009-09-10 | 427,885 | 11.23 | 4,805,149 |
CRIS | Curis Inc | 2009-02-03 | 142,581 | 7.96 | 1,134,945 |
CBIO | Catalyst Biosciences Inc | 2012-11-16 | 3,328 | 7.67 | 25,524 |
CAPS | Capstone Holding Corp | 2011-09-06 | 4,610 | 4.10 | 18,901 |
AOLS | Aeolus Pharmaceuticals Inc | 2005-11-21 | 1,870,000 | 0.00 | 187 |
NTII | Neurobiological Technologies Inc | 2009-10-21 | 331,998 | 0.00 | 33 |
Holding Weightings of Bvf Partners L P/il
Bvf Partners L P/il Form 4 Trading Tracker
According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 0 shares on June 25, 2014, which brought Bvf Partners L P/il around $0.
According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years. The most-recent trade in Neurocrine Biosciences Inc is the acquisition of 29,500 shares on October 12, 2011, which cost Bvf Partners L P/il around $175,820.
According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Arqule Inc (ARQL) over the past 5 years. The most-recent trade in Arqule Inc is the sale of 603,000 shares on April 5, 2010, which brought Bvf Partners L P/il around $4 Million.
More details on Bvf Partners L P/il's insider transactions can be found in the Insider Trading History of Bvf Partners L P/il table.Insider Trading History of Bvf Partners L P/il
- 1
Bvf Partners L P/il Trading Performance
GuruFocus tracks the stock performance after each of Bvf Partners L P/il's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bvf Partners L P/il is 16.03%. GuruFocus also compares Bvf Partners L P/il's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bvf Partners L P/il within 3 months outperforms 43 times out of 88 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Bvf Partners L P/il's insider trading performs compared to the benchmark.
Performance of Bvf Partners L P/il
Bvf Partners L P/il Ownership Network
Ownership Network List of Bvf Partners L P/il
Ownership Network Relation of Bvf Partners L P/il
Bvf Partners L P/il Owned Company Details
What does Five Prime Therapeutics Inc do?
Who are the key executives at Five Prime Therapeutics Inc?
Bvf Partners L P/il is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .
Five Prime Therapeutics Inc (FPRX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Five Prime Therapeutics Inc Insider Transactions
Bvf Partners L P/il Mailing Address
Above is the net worth, insider trading, and ownership report for Bvf Partners L P/il. You might contact Bvf Partners L P/il via mailing address: 44 Montgomery St., 40th Floor, San Francisco Ca 94104.